Anders Waas
Direktor/Vorstandsmitglied bei ALZINOVA AB
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Anders Sandberg | M | 52 | 13 Jahre | |
| Petra Apell | M | 54 |
Texray AB
 Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | 12 Jahre |
| Per-Göran Gillberg | M | 68 | 4 Jahre | |
| Karl Blom | M | 55 | 3 Jahre | |
| Carol Routledge | M | - | 6 Jahre | |
| Anders Torbjörn Ståhlberg | M | - |
Iscaff Pharma AB
 Iscaff Pharma AB Miscellaneous Commercial ServicesCommercial Services Iscaff Pharma AB develops platform and drugs for treatment of cancer. It develops a scaffold technology for drug development and treatment of cancer. The firm's products and services include development support; 3D printed scaffolds; licensing of technologies; and diagnostics. The company was founded by Göran Landberg and Anders Torbjörn Ståhlberg and is headquartered in Gothenburg, Sweden. | - |
| Julian Aleksov | M | 59 | 1 Jahre | |
| Clas Malmeström | M | 59 | 9 Jahre | |
| Göran Landberg | M | - |
Iscaff Pharma AB
Iscaff Pharma AB Miscellaneous Commercial ServicesCommercial Services Iscaff Pharma AB develops platform and drugs for treatment of cancer. It develops a scaffold technology for drug development and treatment of cancer. The firm's products and services include development support; 3D printed scaffolds; licensing of technologies; and diagnostics. The company was founded by Göran Landberg and Anders Torbjörn Ståhlberg and is headquartered in Gothenburg, Sweden. | - |
| Kristina Torfgård | M | 61 | 5 Jahre | |
| Per Haag | M | - | - | |
| Fredrik Gellerstedt | M | - |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | - |
| Stefan Pierrou | M | 59 | 3 Jahre | |
| Stefan Edgren | M | - | - | |
| Kirsten Harting | M | - | 1 Jahre | |
| Sebastian Hansson | M | - | 1 Jahre | |
| Per Vult von Steyern | M | - | - | |
| Margareth Jorvid | F | 63 | 2 Jahre | |
| Uri Peleg | M | - |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | - |
| Pernilla Lindén | F | 55 |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | - |
| Ann-Charlotte Rosendahl | F | 61 |
Sobrera Pharma AB
 Sobrera Pharma AB Pharmaceuticals: MajorHealth Technology Sobrera Pharma AB is a Swedish pharmaceutical company that manufactures products for patients with alcohol use disorders. The company is based in Gothenburg, Sweden. The CEO of the company is Ann-Charlotte Rosendahl. | - |
| Jan Pilebjer | M | 70 |
Implexion Pharma AB
 Implexion Pharma AB Miscellaneous Commercial ServicesCommercial Services Implexion Pharma AB is a Swedish company that focuses on researching and developing drugs. The company is based in Gothenburg, Sweden. | 5 Jahre |
| Per Jesper Dahlberg | M | 60 |
Transmed Gothenburg AB
 Transmed Gothenburg AB Miscellaneous Commercial ServicesCommercial Services Transmed Gothenburg AB provides scientific and technical research and development services. The company is based in Gothenburg, Sweden. | - |
| Mats Johan Alm | M | 61 |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | 5 Jahre |
| Helena Ströberg | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Louis Lange | M | 72 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 19 Jahre |
| Christopher Chai | M | 58 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 Jahre |
| Pernilla Sandwall | F | 61 | - | |
| Lena Birgitta Degling Wikingsson | M | 61 | - | |
| Kenneth Lee | M | 76 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 Jahre |
| Andrew Wolff | M | 69 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 Jahre |
| Huang I-Zu | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 6 Jahre |
| David Banks | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 Jahre |
| Hsiao Lieu | M | 53 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 Jahre |
| Cam Gallagher | M | 54 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 12 Jahre |
| Colin Hislop | M | 66 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 Jahre |
| Markus Jerling | M | 72 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 Jahre |
| Rebecca Lucia | F | 52 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 Jahre |
| Shay Weisbrich | F | 71 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 Jahre |
| Michael T. Sweeney | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 Jahre |
| Paul J. Frohna | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 Jahre |
| Whedy Wang | M | 60 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 9 Jahre |
| Karin Walker | F | 60 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 Jahre |
| Per Wester | M | 64 | 4 Jahre | |
| Anders Bylock | M | 70 | 4 Jahre | |
| Johanna Hultgren | F | 37 | 2 Jahre | |
| Håkan Skogström | M | 63 | 4 Jahre | |
| Philip Wells | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 Jahre |
| Douglas T. Sheehy | M | 57 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 Jahre |
| Bruce Philip Pritchard | M | 51 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 Jahre |
| Peter Hutt | M | 89 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 Jahre |
| Peter M. Strumph | M | 59 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 Jahre |
| Kenneth F. Boehm | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 Jahre |
| R. Greer | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 Jahre |
| Santo Costa | M | 78 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 Jahre |
| Costa G. Sevastopoulos | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Barbara McNeil | M | 83 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 14 Jahre |
| Dan Spiegelman | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 11 Jahre |
| David C. McCaleb | M | 70 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 Jahre |
| John Groom George | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Jennifer Hodge | F | 55 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 Jahre |
| Thomas Shenk | M | 77 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 Jahre |
| Brent Blackburn | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 Jahre |
| Joseph M. Davie | M | 84 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 Jahre |
| Peter G. Milner | M | 68 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 17 Jahre |
| Huw Jones | M | 62 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Thomas L. Gutshall | M | 85 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 15 Jahre |
| Anne Champsaur | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 Jahre |
| Louis Yu | M | 73 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 Jahre |
| Sandra Bevan | F | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 38 | 54,29% |
| Schweden | 28 | 40,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Anders Waas
- Persönliches Netzwerk
